65 related articles for article (PubMed ID: 19159435)
1. Response to imatinib as a function of target kinase expression in recurrent glioblastoma.
Hassler MR; Vedadinejad M; Flechl B; Haberler C; Preusser M; Hainfellner JA; Wöhrer A; Dieckmann KU; Rössler K; Kast R; Marosi C
Springerplus; 2014; 3():111. PubMed ID: 25674429
[TBL] [Abstract][Full Text] [Related]
2. The Glioma Immune Landscape: A Double-Edged Sword for Treatment Regimens.
Mahajan S; Schmidt MHH; Schumann U
Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046685
[TBL] [Abstract][Full Text] [Related]
3. EPHA2 mediates PDGFA activity and functions together with PDGFRA as prognostic marker and therapeutic target in glioblastoma.
Gai QJ; Fu Z; He J; Mao M; Yao XX; Qin Y; Lan X; Zhang L; Miao JY; Wang YX; Zhu J; Yang FC; Lu HM; Yan ZX; Chen FL; Shi Y; Ping YF; Cui YH; Zhang X; Liu X; Yao XH; Lv SQ; Bian XW; Wang Y
Signal Transduct Target Ther; 2022 Feb; 7(1):33. PubMed ID: 35105853
[TBL] [Abstract][Full Text] [Related]
4. Molecular Alterations and Their Correlation With the Survival of Glioblastoma Patients With Corpus Callosum Involvement.
Cui M; Gao X; Chi Y; Zhang M; Lin H; Chen H; Sun C; Ma X
Front Neurosci; 2021; 15():701426. PubMed ID: 34393714
[No Abstract] [Full Text] [Related]
5. Antitumor effects of ribavirin in combination with TMZ and IFN-β in malignant glioma cells.
Ochiai Y; Sumi K; Sano E; Yoshimura S; Yamamuro S; Ogino A; Ueda T; Suzuki Y; Nakayama T; Hara H; Katayama Y; Yoshino A
Oncol Lett; 2020 Nov; 20(5):178. PubMed ID: 32934745
[TBL] [Abstract][Full Text] [Related]
6. ERBB3, IGF1R, and TGFBR2 expression correlate with PDGFR expression in glioblastoma and participate in PDGFR inhibitor resistance of glioblastoma cells.
Song K; Yuan Y; Lin Y; Wang YX; Zhou J; Gai QJ; Zhang L; Mao M; Yao XX; Qin Y; Lu HM; Zhang X; Cui YH; Bian XW; Zhang X; Wang Y
Am J Cancer Res; 2018; 8(5):792-809. PubMed ID: 29888103
[TBL] [Abstract][Full Text] [Related]
7. Translational gap in ongoing clinical trials for glioma.
Guishard AF; Yakisich JS; Azad N; Iyer AKV
J Clin Neurosci; 2018 Jan; 47():28-42. PubMed ID: 29066236
[TBL] [Abstract][Full Text] [Related]
8. Silencing platelet-derived growth factor receptor-β enhances the radiosensitivity of C6 glioma cells
Hong JD; Wang X; Peng YP; Peng JH; Wang J; Dong YP; He D; Peng ZZ; Tu QS; Sheng LF; Zhong MZ; Duan CJ
Oncol Lett; 2017 Jul; 14(1):329-336. PubMed ID: 28693172
[TBL] [Abstract][Full Text] [Related]
9. Coordination of signalling networks and tumorigenic properties by ABL in glioblastoma cells.
Lamballe F; Toscano S; Conti F; Arechederra M; Baeza N; Figarella-Branger D; Helmbacher F; Maina F
Oncotarget; 2016 Nov; 7(46):74747-74767. PubMed ID: 27732969
[TBL] [Abstract][Full Text] [Related]
10. Role of receptor tyrosine kinases and their ligands in glioblastoma.
Carrasco-García E; Saceda M; Martínez-Lacaci I
Cells; 2014 Apr; 3(2):199-235. PubMed ID: 24709958
[TBL] [Abstract][Full Text] [Related]
11. A D-amino acid containing peptide as a potent, noncovalent inhibitor of α5β1 integrin in human prostate cancer invasion and lung colonization.
Veine DM; Yao H; Stafford DR; Fay KS; Livant DL
Clin Exp Metastasis; 2014 Apr; 31(4):379-93. PubMed ID: 24464034
[TBL] [Abstract][Full Text] [Related]
12. In Vitro and In Vivo Analysis of RTK Inhibitor Efficacy and Identification of Its Novel Targets in Glioblastomas.
Martinho O; Silva-Oliveira R; Miranda-Gonçalves V; Clara C; Almeida JR; Carvalho AL; Barata JT; Reis RM
Transl Oncol; 2013 Apr; 6(2):187-96. PubMed ID: 23544171
[TBL] [Abstract][Full Text] [Related]
13. Long-term exposure to imatinib reduced cancer stem cell ability through induction of cell differentiation via activation of MAPK signaling in glioblastoma cells.
Dong Y; Han Q; Zou Y; Deng Z; Lu X; Wang X; Zhang W; Jin H; Su J; Jiang T; Ren H
Mol Cell Biochem; 2012 Nov; 370(1-2):89-102. PubMed ID: 22829019
[TBL] [Abstract][Full Text] [Related]
14. Imatinib and docetaxel in combination can effectively inhibit glioma invasion in an in vitro 3D invasion assay.
Kinsella P; Clynes M; Amberger-Murphy V
J Neurooncol; 2011 Jan; 101(2):189-98. PubMed ID: 20512610
[TBL] [Abstract][Full Text] [Related]
15. Increased potency of the PHSCN dendrimer as an inhibitor of human prostate cancer cell invasion, extravasation, and lung colony formation.
Yao H; Veine DM; Zeng ZZ; Fay KS; Staszewski ED; Livant DL
Clin Exp Metastasis; 2010 Mar; 27(3):173-84. PubMed ID: 20339907
[TBL] [Abstract][Full Text] [Related]
16. In-vitro effects of the tyrosine kinase inhibitor imatinib on glioblastoma cell proliferation.
Ranza E; Mazzini G; Facoetti A; Nano R
J Neurooncol; 2010 Feb; 96(3):349-57. PubMed ID: 19629393
[TBL] [Abstract][Full Text] [Related]
17. Differential effect of imatinib and synergism of combination treatment with chemotherapeutic agents in malignant glioma cells.
Ren H; Tan X; Dong Y; Giese A; Chou TC; Rainov N; Yang B
Basic Clin Pharmacol Toxicol; 2009 Mar; 104(3):241-52. PubMed ID: 19159435
[TBL] [Abstract][Full Text] [Related]
18. STI-571 (Gleevec) potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro.
Wang-Rodriguez J; Lopez JP; Altuna X; Chu TS; Weisman RA; Ongkeko WM
Laryngoscope; 2006 Aug; 116(8):1409-16. PubMed ID: 16885745
[TBL] [Abstract][Full Text] [Related]
19. Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity.
Basciani S; Brama M; Mariani S; De Luca G; Arizzi M; Vesci L; Pisano C; Dolci S; Spera G; Gnessi L
Cancer Res; 2005 Mar; 65(5):1897-903. PubMed ID: 15753388
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
